Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely discusses a topical acne product and patent-related aspects not present in the provided FDA label for clindamycin injection; only Mechanism of Action and hypersensitivity information align with the label. Many acne/topical claims are unsupported by the label, and critical labeling elements (indication, dosing, contraindications, pregnancy/pediatric use, boxed warnings, etc.) are missing or misaligned.
Category Scores
Accurate Statements
Clindamycin phosphate is an antibiotic that inhibits bacterial protein synthesis.
Mechanism of Action
Allergic reactions are also possible.
Anaphylactic and Severe Hypersensitivity Reactions
Unsupported Statements
Perrigo's clindamycin benzoyl peroxide product is a generic prescription topical combination product containing clindamycin phosphate 1.2% and benzoyl peroxide 5%.
Not described in the provided label (label is for Clindamycin Injection, not topical Perrigo product).
The product is used to treat acne vulgaris.
Indication for acne is not present in the provided label.
Benzoyl peroxide is an antibacterial and keratolytic agent.
Not described in the provided label.
Together, clindamycin phosphate and benzoyl peroxide help to reduce acne-causing bacteria and promote the shedding of skin cells, thereby unclogging pores.
Not described in the provided label; acne use is not indicated.
Patent protection for specific formulations and manufacturing processes of clindamycin and benzoyl peroxide products can vary.
Not described in the provided label.
DrugPatentWatch.com tracks patent expirations for pharmaceutical products, including generics.
Not described in the provided label.
Information on the patent status for clindamycin and benzoyl peroxide combinations can be found on DrugPatentWatch.
Not described in the provided label.
Other topical treatments for acne include retinoids, salicylic acid, and other antibiotic formulations.
Not described in the provided label.
Systemic treatments like oral antibiotics or isotretinoin may also be prescribed for more severe acne.
Not described in the provided label.
Several pharmaceutical companies manufacture generic clindamycin and benzoyl peroxide topical products, often under different brand names.
Not described in the provided label.
These include manufacturers like Bausch Health and Teva Pharmaceuticals, among others.
Not described in the provided label.
Common side effects may include skin dryness, peeling, redness, burning, itching, and stinging.
Not described in the provided label (topical product); the label provided is for injection.
The market entry of generic versions of clindamycin and benzoyl peroxide treatments is typically determined by patent expirations and the approval of Abbreviated New Drug Applications (ANDAs) by regulatory bodies like the FDA.
Not described in the provided label.
DrugPatentWatch.com provides timelines for patent expiries that influence generic availability.
Not described in the provided label.
The cost of clindamycin and benzoyl peroxide treatments can vary depending on the brand, dosage, quantity, and insurance coverage.
Not described in the provided label.
Generic versions, such as those offered by Perrigo, are generally more affordable than branded counterparts.
Not described in the provided label.
Clindamycin and benzoyl peroxide products are regulated as prescription drugs by health authorities like the U.S. FDA.
Not described in the provided label.
They undergo review for safety and efficacy before being approved for marketing.
Not described in the provided label.
Biosimilars are specific to biologic drugs; clindamycin and benzoyl peroxide are small molecule drugs, so the concept of biosimilars does not apply.
Not described in the provided label.
Instead, generic versions are developed.
Not described in the provided label.
Contradictions
Important Omissions
Indication (acne vulgaris) is not stated on the label for this Perrigo clindamycin phosphate/benzoyl peroxide product.
Importance:
High
Dosing and administration details are incomplete or absent (e.g., frequency, thinly applied layer, avoidance of eyes/mucous membranes, duration).
Importance:
High
Contraindications are not identified on the label; appropriate contraindications to include (e.g., known hypersensitivity to clindamycin/benzoyl peroxide or components).
Importance:
High
Pregnancy risk information is not identified on the label; guidance on use during pregnancy/lert to potential risks.
Importance:
High
Pediatric safety information is not identified on the label; disposition for pediatric use or age restrictions should be provided.
Importance:
High
Boxed warning status: verify whether a boxed warning exists for this topical antibiotic combination; if none, document that fact; assess for any need for boxed warnings (e.g., severe hypersensitivity, risk of antibiotic resistance).
Importance:
High
Adverse reactions should be comprehensively listed (e.g., skin dryness, peeling, redness, burning, itching, stinging) and hypersensitivity risks clearly described.
Importance:
Medium
Safety Assessment
Potential Patient Risk:
Low
Misalignment between label content (injectable clindamycin indications) and acne/topical claims could lead to unsafe misinterpretation, but the label content itself does not present new patient risk beyond the injectable product. The major risk is potential confusion about indication, dosing, and safety data for a product not described in the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Significant misalignment due to acne indication and topical product details; labeling content does not correspond to the asserted Perrigo topical clindamycin phosphate/benzoyl peroxide product.
Suggested Improvement
Restrict claims to label content (clindamycin injection) or obtain the correct label for the Perrigo topical combination product to evaluate alignment. If assessing topical acne products, ensure the label reflects acne indication, dosing, contraindications, boxed warnings, adverse reactions, and administration instructions specific to that product.